comparemela.com

Latest Breaking News On - Fcpm iii services - Page 5 : comparemela.com

UBS Group Initiates Coverage on enGene (NASDAQ:ENGN)

UBS Group Initiates Coverage on enGene (NASDAQ:ENGN)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Leerink-partnrs
Omega-fund-management
Fcpm-iii-services
Gene-holdings-inc
Morgan-stanley
Nasdaq
Blue-owl-capital-holdings
Gene-company-profile
Goldman-sachs-group-inc
Dgene-inc
Get-free-report
Gene-price

NewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume

Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) saw strong trading volume on Tuesday . 195,163 shares changed hands during trading, a decline of 19% from the previous session’s volume of 239,915 shares.The stock last traded at $22.48 and had previously closed at $22.46. Analyst Ratings Changes A number of research firms have recently […]

Canada
Newamsterdam-pharma
Piper-sandler
Louisg-lange
Newamsterdam-pharma-company
Opaleye-management-inc
Scotiabank
Goldman-sachs-group-inc
Parkman-healthcare-partners
Royal-bank
Newamsterdam-pharma-company-profile
Fcpm-iii-services

Replimune Group (NASDAQ:REPL) Trading Up 5.3%

Replimune Group (NASDAQ:REPL) Trading Up 5.3%
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Barclays
News-ratings-for-replimune-group-daily
Goldman-sachs-group-inc
Fcpm-iii-services
Replimune-group-inc
Replimune-group-company-profile
Replimune-group-price-performance
Replimune-group
Institutional-investors-weigh-in-on-replimune-group
Pricet-rowe-associates-inc
Nasdaq

Chardan Capital Increases Dyne Therapeutics (NASDAQ:DYN) Price Target to $31.00

Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target hoisted by Chardan Capital from $20.00 to $31.00 in a research note issued to investors on Friday, Stock Target Advisor reports. The brokerage currently has a buy rating on the stock. Several other research firms have also weighed in on DYN. StockNews.com upgraded shares of […]

United-states
Piper-sandler
Raymond-james
Oxana-beskrovnaya
Dirk-kersten
Stifel-nicolaus
Securities-exchange-commission
Dyne-therapeutics-inc
Blackrock-inc
Fcpm-iii-services
Goldman-sachs-group-inc
Vr-adviser

enGene (NASDAQ:ENGN) Earns Overweight Rating from Analysts at Morgan Stanley

Morgan Stanley started coverage on shares of enGene (NASDAQ:ENGN – Free Report) in a research note published on Friday, MarketBeat reports. The brokerage issued an overweight rating and a $40.00 target price on the stock. ENGN has been the topic of several other reports. Leerink Partnrs reaffirmed an outperform rating on shares of enGene in […]

Leerink-partnrs
Omega-fund-management
Vivo-capital
Blue-owl-capital-holdings
Gene-holdings-inc
Fcpm-iii-services
Morgan-stanley
Dgene-inc
Free-report
Gene-stock
Owl-capital-holdings
Fund-management

vimarsana © 2020. All Rights Reserved.